So far, all I have disclosed about why I am accumulating CLDX is it was this years ‘ASCO’ star.  I have 4k at 7.58 average shares.  Read this below, and you can see why I am high on this company.  Right now, no stop in mind, waiting for it’s merger to close this QTR before new data is released.  Just a hold for now, small to medium position.

http://in.sys-con.com/node/1050356

Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved

In addition to Provenge, other therapeutic vaccines in development for cancer include Merck KGaA’s Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer’s CDX-110 for glioblastoma multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing to an impressive effect on overall survival in Phase II clinical trials.

Therapeutic cancer vaccines are likely to command a high price. Although most surveyed clinicians expect to prescribe these agents, a minority of surveyed managed care organizations’ (MCO) pharmacy directors expect to place Provenge, Stimuvax and CDX-110 on the top two tiers of their formularies. Only 25 percent of surveyed MCOs expect to place Provenge on tier one or tier two of their formularies, assuming the vaccine is priced in line with Roche/Chugai’s Avastin. Additionally, of surveyed MCOs, 30 percent expect to place Stimuvax on the top two tiers of their formularies and 35 percent expect to place CDX-110 on the top two tiers of their formularies.